Abbott to acquire Exact Sciences for $21 billion
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The deliveries bring the innovative medicine to communities heavily impacted by HIV just five months after U.S. FDA approval
The proposed transaction will be effected as a share swap
Call it a major milestone in bladder cancer therapy that aims to provide a lifeline for patients who previously had limited options
These certifications reflect the company's continuous commitment to maintaining international standards of environmental sustainability as well as occupational health and safety
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
The company will soon be launching a new portfolio of products in this segment
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
The non-dilutive financing includes three tranches
Subscribe To Our Newsletter & Stay Updated